BOSTON, Aug. 6, 2024 /PRNewswire/ -- Servier today announced that the U.S. Food and Drug Administration (FDA) has approved VORANIGO®, an isocitrate dehydrogenase-1 (IDH1) and isocitrate ...

Voranigo (vorasidenib) can cause side effects that range from mild to serious. More common side effects include fatigue, headache, and diarrhea. If side effects from Voranigo become difficult to ...

Treatment with vorasidenib significantly improved progression free survival compared with placebo. The Food and Drug Administration (FDA) has approved Voranigo (vorasidenib) for the treatment of adult ...

Voranigo extends progression-free survival and delays further treatment in IDH-mutated grade 2 glioma patients post-surgery. The treatment reduces tumor growth and seizure frequency without affecting ...

Voranigo demonstrated disease stability in 53.1% of patients with grade 3 or 4 IDH-mutant gliomas over 3.5 months. The study included 32 patients, most of whom had extensive prior treatments, ...

BOSTON, July 25, 2025 /PRNewswire/ -- Servier today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion ...

Voranigo (vorasidenib) is not safe to take while pregnant or breastfeeding. Certain factors, including the risk fetal harm, may determine whether you should take the drug during this time. Voranigo is ...

LAVAL, QC, Feb. 27, 2026 /CNW/ - Servier Canada is pleased to announce that VORANIGO® (vorasidenib tablets) is now publicly reimbursed in Ontario under the province's Funding Accelerated for Specific ...

Voranigo (vorasidenib) is a prescription oral tablet approved to treat certain brain tumors. This drug is not considered safe to take while pregnant or breastfeeding and may affect fertility. If you ...